Do urinary phthalate metabolites and butylparaben indicate exposure to EDCs that lower testosterone and disrupt androgen signaling?

Urinary concentrations of phthalate metabolites (such as mono(2-ethylhexyl) phthalate [MEHP] and mono-n-butyl phthalate [MnBP]) and butylparaben serve as established biomarkers that accurately reflect human exposure to endocrine-disrupting chemicals (EDCs), primarily entering the body via personal-care and consumer products.

Clinical and epidemiological evidence

• Epidemiological data from major cohorts, including the National Health and Nutrition Examination Survey (NHANES) and the Environment and Reproductive Health (EARTH) study, consistently demonstrate that higher urinary concentrations of these EDCs are associated with lower serum total and free testosterone in men.
• This reduction in circulating testosterone is especially pronounced in older demographics, highlighting a heightened vulnerability to reproductive hormone disruption with age.

Mechanistic explanations

• The primary biological pathway involves the suppression of steroidogenesis in testicular Leydig cells. Phthalate exposure downregulates critical steroidogenic genes, specifically Star, Cyp11a1, and Hsd3b, directly reducing the cells' capacity to synthesize testosterone.
• Furthermore, in silico and in vitro analyses demonstrate that phthalate metabolites bind directly to the androgen receptor (AR) ligand-binding domain. This competitive inhibition blocks natural testosterone binding, disrupting downstream androgen signaling and impairing masculine endocrine pathways.

Bottom line

• Urinary phthalate metabolites and butylparaben serve as highly reliable biomarkers of EDC exposure, which is scientifically proven to lower testosterone and disrupt male androgen signaling by directly suppressing Leydig cell steroidogenesis and competitively blocking androgen receptor activity.